New biomarker may guide best use of KRAS inhibitors in lung cancer

Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

June 20, 2025

Vol.51 No.24

By Otis W. Brawley and Paul Goldberg

In Brief

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

City of Hope has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the U.S. Department of Health and Human Services. The grant will help City of Hope create a biomap of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Cancer Policy

In “Bethesda Declaration,” NIH employees, Nobel laureates say Bhattacharya is favoring politics over U.S. science, health

NIH Director Jayanta Bhattacharya “prioritizes political momentum over human safety and faithful stewardship of public resources,” a group of Nobel laureates and over 300 NIH employees wrote in a letter.

Samir S. Taneja named head of Northwell Health’s urology service line

Samir S. Taneja was selected to lead Northwell Health’s urology service line. He was appointed senior vice president, Northwell’s system chair of urology, and chair of the Smith Institute for Urology at Northwell Health.

June 13, 2025

Vol.51 No.23

New biomarker may guide best use of KRAS inhibitors in lung cancer

YOU MAY BE INTERESTED IN

Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In “Bethesda Declaration,” NIH employees, Nobel laureates say Bhattacharya is favoring politics over U.S. science, health

Samir S. Taneja named head of Northwell Health’s urology service line

Renew today!

Subscriber content

Never miss an issue!

Login